Cyclin-dependent kinase 2 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Cyclin-dependent kinase 2 shows late clinical disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P24941. Start with chronic lymphocytic leukemia, then reuse UniProt P24941 as the stable protein anchor across project notes and exports.
Start with chronic lymphocytic leukemia, then reuse UniProt P24941 as the stable protein anchor across project notes and exports.
Cyclin-dependent kinase 2 shows late clinical disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.
Start review with chronic lymphocytic leukemia because it currently carries late clinical support. Linked drugs include ALVOCIDIB, BMS-387032, DINACICLIB, ZOTIRACICLIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyCyclin-dependent kinase 2
Review this target as Cyclin-dependent kinase 2, mapped to UniProt P24941. Sequence length is 298 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Cyclin-dependent kinase 2 as ChEMBL target CHEMBL301, mapped to UniProt P24941. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Cyclin-dependent kinase 2 is the right protein anchor across sources, using UniProt P24941 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why chronic lymphocytic leukemia is currently framed as late clinical support. It currently carries 4 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Cyclin-dependent kinase 2 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P24941 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Cyclin-dependent kinase 2 |
| UniProt Accession | P24941 |
| Component Type | Protein |
| Sequence Length | 298 aa |
Cyclin-dependent kinase 2
Review this target as Cyclin-dependent kinase 2, mapped to UniProt P24941. Sequence length is 298 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Cyclin-dependent kinase 2 shows late clinical disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block.
Start review with chronic lymphocytic leukemia because it currently carries late clinical support. Linked drugs include ALVOCIDIB, BMS-387032, DINACICLIB, ZOTIRACICLIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4446357 | 10.05 | Ki | 0.09 | Clinical |
| CHEMBL388978 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL526110 | 9.52 | IC50 | 0.3 | Preclinical |
| CHEMBL317703 | 9.48 | IC50 | 0.33 | Preclinical |
| CHEMBL321517 | 9.47 | IC50 | 0.34 | Preclinical |
| CHEMBL476577 | 9.3 | IC50 | 0.5 | Preclinical |
| CHEMBL384304 | 9.28 | Kd | 0.53 | Clinical |
| CHEMBL1964259 | 9.27 | IC50 | 0.54 | Preclinical |
| CHEMBL4088242 | 9.1 | IC50 | 0.8 | Preclinical |
| CHEMBL3919361 | 9.07 | IC50 | 0.857 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 758 | 2,043 | 6.7 |
| cell-based format | 187 | 222 | 6.6 |
| assay format | 74 | 55 | 6.1 |
| subcellular format | 40 | 23 | 6.5 |
| biochemical format | 1 | 0 | — |
| tissue-based format | 1 | 15 | 6.3 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 55 | 1 | 4.8 |
| assay format | 2 | 395 | 6.3 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 5 | 12 | 7.8 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 0 | — |